Physiologically Based Pharmacokinetic Modeling of Venetoclax in Pediatric Acute Myeloid Leukemia: Food Effects, Age-Related Pharmacokinetics, and Voriconazole-Mediated Drug-Drug Interactions.
- 1Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
- 2Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China.
- 3Department of Leukemia, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.
Abstract
Background: Venetoclax (VEN), a selective B-cell lymphoma 2 inhibitor, has been increasingly used off-label in pediatric patients with hematologic malignancies. However, its pharmacokinetic characteristics in pediatric patients remain insufficiently characterized. Methods: An adult VEN physiologically based pharmacokinetic (PBPK) model was developed and extrapolated to children using age-dependent physiological and CYP3A4 ontogeny data. The pediatric model was calibrated and evaluated using data from 76 children with AML (203 plasma concentrations) and subsequently applied to assess food effects, age-related pharmacokinetic differences, and VEN dose-reduction scenarios during VCZ co-administration. The clinical study was registered with the Chinese Clinical Trial Registry (ChiCTR1900027146 and ChiCTR2400080307). Results: The adult and pediatric models adequately reproduced the observed VEN concentration-time profiles. At 200 mg/m², a normal-fat meal increased predicted AUCinf and Cmax by 2.74- and 1.77-fold, respectively, versus a low-fat meal. Children aged 2-<6 years had the highest exposure; AUCinf was 1.44- and 1.91-fold higher than in the 6-<12- and 12-<18-year groups, respectively. During VCZ co-administration, reducing VEN to 50% and 25% of the full dose decreased AUC0-168h by 36.8% and 60.5% and Cmax by 42.5% and 70.5%, respectively, with minimal changes in Tmax. Conclusions: The pediatric VEN PBPK model quantitatively characterized the effects of meal conditions, developmental age, and VCZ-mediated CYP3A inhibition on VEN pharmacokinetics. These findings support administration with a normal diet, closer safety monitoring in children aged 2-<6 years receiving 200 mg/m², and model-informed evaluation of VEN dose reduction during concomitant VCZ therapy.
Related
- Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children
- Physiologically-based pharmacokinetic model to predict pharmacokinetics of KY0467 in humans and guide dose selection in infants and children
- Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions of Aficamten in the Chinese Population.
- Evaluation of Voriconazole Population Pharmacokinetics in Japanese Patients and Factors Influencing Prediction Accuracy: A Machine Learning Approach
- Introduction to Single‐Cell Physiologically‐Based Pharmacokinetic (scPBPK) Models
BibTeX
@article{li2026physiologically,
title = {{Physiologically Based Pharmacokinetic Modeling of Venetoclax in Pediatric Acute Myeloid Leukemia: Food Effects, Age-Related Pharmacokinetics, and Voriconazole-Mediated Drug-Drug Interactions.}},
author = {Yanming Li and Mengmeng Liu and Qixian Ling and Ning Sun and Huyong Zheng and Peng Guo and Libo Zhao},
journal = {Pharmaceutics},
year = {2026},
month = oct,
doi = {10.3390/pharmaceutics18101335},
url = {https://europepmc.org/article/MED/42942864},
note = {CC BY},
}
RIS
TY - JOUR
TI - Physiologically Based Pharmacokinetic Modeling of Venetoclax in Pediatric Acute Myeloid Leukemia: Food Effects, Age-Related Pharmacokinetics, and Voriconazole-Mediated Drug-Drug Interactions.
AU - Yanming Li
AU - Mengmeng Liu
AU - Qixian Ling
AU - Ning Sun
AU - Huyong Zheng
AU - Peng Guo
AU - Libo Zhao
PY - 2026
DA - 2026/10/21
JO - Pharmaceutics
DO - 10.3390/pharmaceutics18101335
UR - https://europepmc.org/article/MED/42942864
AB - Background: Venetoclax (VEN), a selective B-cell lymphoma 2 inhibitor, has been increasingly used off-label in pediatric patients with hematologic malignancies. However, its pharmacokinetic characteristics in pediatric patients remain insufficiently characterized. Methods: An adult VEN physiologically based pharmacokinetic (PBPK) model was developed and extrapolated to children using age-dependent physiological and CYP3A4 ontogeny data. The pediatric model was calibrated and evaluated using data from 76 children with AML (203 plasma concentrations) and subsequently applied to assess food effects, age-related pharmacokinetic differences, and VEN dose-reduction scenarios during VCZ co-administration. The clinical study was registered with the Chinese Clinical Trial Registry (ChiCTR1900027146 and ChiCTR2400080307). Results: The adult and pediatric models adequately reproduced the observed VEN concentration-time profiles. At 200 mg/m², a normal-fat meal increased predicted AUCinf and Cmax by 2.74- and 1.77-fold, respectively, versus a low-fat meal. Children aged 2-<6 years had the highest exposure; AUCinf was 1.44- and 1.91-fold higher than in the 6-<12- and 12-<18-year groups, respectively. During VCZ co-administration, reducing VEN to 50% and 25% of the full dose decreased AUC0-168h by 36.8% and 60.5% and Cmax by 42.5% and 70.5%, respectively, with minimal changes in Tmax. Conclusions: The pediatric VEN PBPK model quantitatively characterized the effects of meal conditions, developmental age, and VCZ-mediated CYP3A inhibition on VEN pharmacokinetics. These findings support administration with a normal diet, closer safety monitoring in children aged 2-<6 years receiving 200 mg/m², and model-informed evaluation of VEN dose reduction during concomitant VCZ therapy.
SN - 1999-4923
ER -